CD47 and neoplasm: It remains unclear why B6H12 in solution exhibit slower kinetics compared to soluble CC2C6, however, having two different monoclonal antibodies able to induce cell death in a CD47-dependent manner affirms the strategy of targeting CD47 as an anti-tumour therapy.